Dermatology
Conference Coverage
Children With Severe Atopic Dermatitis Catch Up on Growth With Dupilumab
Children at the lower percentiles of height receiving prompt treatment with dupilumab “were able to rapidly move through the centiles over the 16...
Latest News
Nemolizumab Benefits for Atopic Dermatitis Maintained in Long-Term Follow-Up Study
Nemolizumab was associated with “ongoing clinically meaningful improvements in itch, skin lesions, and sleep disturbance,” reported Dr. Diamant...
Latest News
Rosacea: Ivermectin’s Benefits May Include Impact on Skin Microbiome
The absolute abundance of S epidermidis increased after ivermectin treatment on lesional skin of patients with rosacea.
Latest News
Skin Fungal Infections Increasing in the United States
The analysis included over 13 billion ambulatory visits to nonfederally funded community, office-based physician practices, and emergency or...
Latest News
Cosmetic Dermatology Product Recalls Still Common, Analysis Finds
During the study period, 334 voluntary and manufacturer-initiated recalls of cosmetic products were reported, affecting 77,135,700 units.
Conference Coverage
Parent Perceptions Drive Diet Changes for Children With Atopic Dermatitis
The current study highlights the need for more awareness of the limited impact of dietary modifications on atopic dermatitis in the absence of...
Latest News
Atopic Dermatitis: Upadacitinib Effectiveness Maintained Through 76 weeks Among Adolescents
Among those who continued treatment on upadacitinib, 15 mg and 30 mg, EASI-75 response rates were maintained or improved through week 76 in three...
Latest News
Increase in Troublesome Fungal Infections Requires All-Out Approach
“Trichophyton indotineae is changing the way we talk about dermatophyte infections,” said Avrom S. Caplan, MD, a dermatologist at New...
Latest News
A Dermatologist’s Tips for Supporting LGBTQ Youth
Dermatologists have a unique opportunity to transform the healthcare landscape for LGBTQ children and adolescents, according to Dr. Markus Boos....
Latest News
Responses Sustained with Ritlecitinib in Patients with Alopecia Through 48 Weeks
Among patients on ritlecitinib who had responded at week 24, SALT responses ≤ 20 were sustained in 85.2%-100% of patients through week 48.
Latest News
Over 3 Years, Atopic Dermatitis Well-Controlled with Lebrikizumab
“Over the whole follow-up, 90% had no need for topical corticosteroids or any other rescue therapy,” reported Diamant Thaçi, MD, PhD.